Envestnet Asset Management Inc. Has $4.41 Million Position in Certara, Inc. (NASDAQ:CERT)

Envestnet Asset Management Inc. cut its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 9.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 414,056 shares of the company's stock after selling 43,117 shares during the period. Envestnet Asset Management Inc. owned approximately 0.26% of Certara worth $4,410,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Samjo Management LLC purchased a new position in Certara in the 4th quarter valued at approximately $2,024,000. Wells Fargo & Company MN boosted its position in shares of Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares in the last quarter. ExodusPoint Capital Management LP purchased a new stake in shares of Certara in the fourth quarter valued at about $11,542,000. Massachusetts Financial Services Co. MA increased its stake in shares of Certara by 4.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company's stock worth $43,494,000 after purchasing an additional 182,042 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC lifted its position in shares of Certara by 20.5% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,943 shares of the company's stock valued at $138,000 after acquiring an additional 2,202 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Stock Performance

Shares of CERT stock traded down $0.25 during trading hours on Friday, reaching $14.17. 1,549,489 shares of the company's stock were exchanged, compared to its average volume of 1,219,702. The business has a fifty day moving average price of $11.65 and a 200-day moving average price of $11.57. The stock has a market capitalization of $2.29 billion, a P/E ratio of -70.85, a P/E/G ratio of 9.29 and a beta of 1.64. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $17.94.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. KeyCorp boosted their price objective on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. TD Cowen started coverage on Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price on the stock. Robert W. Baird lifted their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Barclays lowered their price target on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Finally, Stephens reissued an "overweight" rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Certara currently has an average rating of "Moderate Buy" and an average price target of $15.17.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.